Modulation of osteoclast formation.

[1]  J. Yodoi,et al.  Regulation of Human Osteoclast Differentiation by Thioredoxin Binding Protein‐2 and Redox‐Sensitive Signaling , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Gillespie,et al.  Characterization of Sugar Binding by Osteoclast Inhibitory Lectin* , 2004, Journal of Biological Chemistry.

[3]  T. Martin,et al.  Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. , 2004, Arthritis and rheumatism.

[4]  T. Taniguchi,et al.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis , 2004, Nature.

[5]  Kozo Nakamura,et al.  PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. , 2004, The Journal of clinical investigation.

[6]  Aubie K. Shaw,et al.  IL-6, LIF, and TNF-α regulation of GM-CSF inhibition of osteoclastogenesis in vitro , 2004 .

[7]  S. Gasser,et al.  Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Dammacco,et al.  Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L , 2004, Leukemia & lymphoma.

[9]  M. Kirkland,et al.  Osteoclastic Potential of Human CFU‐GM: Biphasic Effect of GM‐CSF , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  W. McKinstry,et al.  Isolation of a Human Homolog of Osteoclast Inhibitory Lectin That Inhibits the Formation and Function of Osteoclasts , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  J. Edwards,et al.  LIGHT (TNFSF14), a novel mediator of normal and pathological bone resorption. , 2004 .

[12]  H. Bergmeister,et al.  Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. , 2004, Arthritis and rheumatism.

[13]  M. Rogers.  New insights into the molecular mechanisms of action of bisphosphonates. , 2003, Current pharmaceutical design.

[14]  J. Finkelstein,et al.  The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.

[15]  D. Fremont,et al.  Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors , 2003, Nature Immunology.

[16]  H. Bergmeister,et al.  Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. , 2003, Arthritis and rheumatism.

[17]  M. Wani,et al.  IL-3 Acts Directly on Osteoclast Precursors and Irreversibly Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation by Diverting the Cells to Macrophage Lineage1 , 2003, The Journal of Immunology.

[18]  N. Horwood,et al.  T‐Cells Mediate an Inhibitory Effect of Interleukin‐4 on Osteoclastogenesis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  M. Gillespie,et al.  Osteoclast Inhibitory Lectin, a Family of New Osteoclast Inhibitors* , 2002, The Journal of Biological Chemistry.

[20]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[21]  U. Lerner,et al.  Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. , 2002, Bone.

[22]  T. Taniguchi,et al.  Signaling crosstalk between RANKL and interferons in osteoclast differentiation , 2002, Arthritis research.

[23]  J. Hamilton,et al.  The generation of highly enriched osteoclast-lineage cell populations. , 2002, Bone.

[24]  T. Suda,et al.  Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.

[25]  Hisataka Yasuda,et al.  Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  N. Fazzalari,et al.  The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  W. McKinstry,et al.  A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation* , 2001, The Journal of Biological Chemistry.

[28]  T. Martin,et al.  IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro1 , 2001, The Journal of Immunology.

[29]  Paul J. Williams,et al.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.

[30]  T. Willson,et al.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Martin,et al.  Fibroblastic Stromal Cells Express Receptor Activator of NF‐κB Ligand and Support Osteoclast Differentiation , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  T. Martin,et al.  Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .

[33]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[34]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[35]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[36]  R. Derynck,et al.  Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. , 1999, Development.

[37]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[38]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[39]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[40]  T. Martin,et al.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.

[41]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[42]  M. Gillespie,et al.  Osteoclasts from Human Giant Cell Tumors of Bone Lack Estrogen Receptors* , 2022 .

[43]  H. Okamura,et al.  Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. , 1998, The Journal of clinical investigation.

[44]  T. Era,et al.  Development of osteoclasts from embryonic stem cells through a pathway that is c-fms but not c-kit dependent. , 1997, Blood.

[45]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[46]  H. Okamura,et al.  Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. , 1997 .

[47]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[48]  T. Martin,et al.  Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. , 1997, Endocrinology.

[49]  T. Chambers,et al.  IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. , 1996, Journal of immunology.

[50]  R. Derynck,et al.  Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype , 1996, The Journal of cell biology.

[51]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.

[52]  S. Clark,et al.  Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts , 1993, The Journal of experimental medicine.

[53]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[54]  L. Bonewald,et al.  Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. , 1989, Biochemical and biophysical research communications.